STEM, INC.

STEM, INC.STEMEarnings & Financial Report

NYSE · Information Technology · Services-Computer Integrated Systems Design

StemCells, Inc. is a public biopharmaceutical company headquartered in Newark, California, that is developing purified human neural stem cells (HuCNS-SCs) in the hopes of treating central nervous system disorders and paralysis. StemCells' HuCNS-SCs have the ability to differentiate into the three main types of cells found in the central nervous system: neurons, astrocytes and oligodendrocytes.

Top Holders

Holder% OwnedSharesChangeAs of
BlackRock, Inc.7.30%
11.4M
2024-01-26
Schroder Investment Management Limited6.80%
10.6M
2024-02-13
The Vanguard Group5.32%
8.7M
flat2024-11-12
Schroder Investment Management North America Inc5.00%
2024-11-14

Insider Transactions

Net 90d: $114.2K · buys $0 / sells $114.2K
Range:
Action:
Role:
InsiderRoleAction
2026-03-11Matthew TappinPresident, Software ProductsSell (open market)
402
$10.83$4.4K
2026-03-10Matthew TappinPresident, Software ProductsSell (open market)
655
$11.12$7.3K
2026-03-10Arun NarayananChief Executive OfficerSell (open market)
5.1K
$11.12$57.2K
2026-03-10Laureles Saul R.Chief Legal OfficerSell (open market)
942
$11.12$10.5K
2026-03-10Carlson Michael JamesPresident, Managed ServicesSell (open market)
2.1K
$11.12$23.1K
2026-03-07Matthew TappinPresident, Software ProductsOption exercise
1.5K
2026-03-07Arun NarayananChief Executive OfficerOption exercise
12.5K
2026-03-07Arun NarayananChief Executive OfficerOption exercise
5.6K
2026-03-07Laureles Saul R.Chief Legal OfficerOption exercise
2.9K
2026-03-07Carlson Michael JamesPresident, Managed ServicesOption exercise
3.5K
110 of 19
Page 1 / 2